| Idorsia Pharmaceuticals Japan; Idorsia Pharmaceuticals Korea | Nxera Pharma | $466m | Jul, 2023 | Acquisition |
|---|---|---|---|---|
| Asia Rights of Two Immune Therapies | Nanjing Huadong Pharmaceutical | $383m | Aug, 2024 | Asset Transaction |
| Sasaeah Pharmaceutical | Virbac Group | $304m | Mar, 2024 | Acquisition |
| I'rom Group | BXJB II Holding | $188m | May, 2024 | Acquisition |
| Daiichi Sankyo Espha | Qol | $184m | May, 2023 | Acquisition |